On May 4, 2020 TargetRx, a Shenzhen company developing small molecules therapeutics for cancer, reported that it has completed a $21.2 million Series A financing, led by CCB Principal Capital Management (Press release, Shenzhen TargetRx, MAY 4, 2020, View Source [SID1234556985]). Founded in 2014, the company is developing novel third/fourth generation candidates with the goal of avoiding acquired drug resistance. Proceeds from the funding will be used for clinical studies of the company’s chronic myeloid leukemia and non-small cell lung cancer treatments and other R&D. The founder of TargetRx, Dr. Yihan Wang, has previously discovered several first-in-class novel drugs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!